If you’re a federal employee and have questions about continuing coverage, please speak to your Patient Benefits Specialist and visit our insurance page here: virginiacancerspecialists.com/insurance/. Exciting News! Our Gainesville Office has moved to Bristow – 9450 Innovation Drive, Manassas, VA 20110. Same great providers and care team, same exceptional care, new, larger space to better serve our patients.
A monoclonal antibody against mannan-binding lectin (MBL)-associated serine protease-2 (MASP-2), with potential anti-thrombotic and immunomodulating activities. Upon subcutaneous administration, OMS721 binds to and inhibits MASP-2. This prevents the activation of MASP-2, the cleavage of certain complement components, and the activation of the complement lectin pathway. This inhibits complement deposition and complement-induced thrombus formation. MASP-2, a pro-inflammatory protein, plays a key role in the activation of the lectin complement pathway, which is a key component in the immune system, and is associated with complement-mediated diseases, such as thrombotic microangiopathies (TMAs), which includes hematopoietic stem cell transplant (HSCT)-related TMA, atypical hemolytic uremic syndrome (aHUS), and thrombotic thrombocytopenic purpura (TTP). Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
